Background: The atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy associated with high morbidity and high mortality. Eculizumab, a humanized anti-C5 monoclonal antibody, was the first medication approved for treating aHUS in 2011.
Objective: The objective of this study is to evaluate the efficacy and safety of eculizumab treatment in pediatric patients with aHUS.